Abstract
Cancer is a leading cause of death worldwide. The expression of COX-2 and prostaglandins has not only been associated with various types of cancer but is also directly proportional to their aggressiveness including metastasis. Thus, inhibition of COX-2 activity has been one of the preferred targets for cancer reduction. Broad spectrum inhibition of all forms of COX (using NSAIDs) is associated with various side effects ranging from gastric ulceration to renal problems. Even specific COX-2 inhibitors (COXIBs) are associated with side effects like myocardial infarction. Alternative strategies including siRNA technology are also not very victorious due to their off-target associated problems. Thus, there is an urgent need for the development of strategies where COX-2 activity may be reduced without inducing any side effects. One of the approaches for designing novel inhibitors may be to target various molecules downstream of COX-2. In this review, we have tried to cover the basic biology of COX-2 and its association with different types of cancer. Various generations of COX-2 inhibitors have been covered with their merits and demerits. Possible exploitation of novel targets like EP receptors, mPGES and various other downstream molecules which can be utilized for a better COX-2 signaling inhibition and thus efficient cancer reduction with minimal side effects has been discussed.
Keywords: Cancer, COXIBs, cyclooxygenase-2, NSAIDs, mPGES-1, EP receptors.
Current Drug Targets
Title:COX-2 Signaling and Cancer: New Players in Old Arena
Volume: 15 Issue: 3
Author(s): Shashank Misra and Kulbhushan Sharma
Affiliation:
Keywords: Cancer, COXIBs, cyclooxygenase-2, NSAIDs, mPGES-1, EP receptors.
Abstract: Cancer is a leading cause of death worldwide. The expression of COX-2 and prostaglandins has not only been associated with various types of cancer but is also directly proportional to their aggressiveness including metastasis. Thus, inhibition of COX-2 activity has been one of the preferred targets for cancer reduction. Broad spectrum inhibition of all forms of COX (using NSAIDs) is associated with various side effects ranging from gastric ulceration to renal problems. Even specific COX-2 inhibitors (COXIBs) are associated with side effects like myocardial infarction. Alternative strategies including siRNA technology are also not very victorious due to their off-target associated problems. Thus, there is an urgent need for the development of strategies where COX-2 activity may be reduced without inducing any side effects. One of the approaches for designing novel inhibitors may be to target various molecules downstream of COX-2. In this review, we have tried to cover the basic biology of COX-2 and its association with different types of cancer. Various generations of COX-2 inhibitors have been covered with their merits and demerits. Possible exploitation of novel targets like EP receptors, mPGES and various other downstream molecules which can be utilized for a better COX-2 signaling inhibition and thus efficient cancer reduction with minimal side effects has been discussed.
Export Options
About this article
Cite this article as:
Misra Shashank and Sharma Kulbhushan, COX-2 Signaling and Cancer: New Players in Old Arena, Current Drug Targets 2014; 15 (3) . https://dx.doi.org/10.2174/1389450115666140127102915
DOI https://dx.doi.org/10.2174/1389450115666140127102915 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protease-Activated Receptors (PARs) as Therapeutic Targets: Development of Agonists / Antagonists and Modulation of Gastrointestinal Functions
Drug Design Reviews - Online (Discontinued) Pioglitazone and Rosiglitazone: Effects of Treatment with a Thiazolidinedione on Lipids and Non Conventional Cardiovascular Risk Factors
Current Clinical Pharmacology Genomics of Fungal Disease Resistance in Tomato
Current Genomics 2-Aminoethyldiphenyl Borinate: A Multitarget Compound with Potential as a Drug Precursor
Current Molecular Pharmacology Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Multiple Sclerosis (MS): A Critical Review
CNS & Neurological Disorders - Drug Targets Design, Synthesis, Computational and Biological Evaluation of Two New Series of 1, 3- and 1,6-dihydroxy Xanthone Derivatives as Selective COX-2 Inhibitors
Letters in Drug Design & Discovery Prospect of Individualized Medicine in Chronic Hepatitis C Therapy by Pharmacogenomics
Current Pharmacogenomics Relationship between Fatty Acid Habitual Intake and Early Inflammation Biomarkers in Individuals with and without Type 2 Diabetes in Mexico
Endocrine, Metabolic & Immune Disorders - Drug Targets Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology Antioxidant and Anti-Inflammatory Activity of Aryl-Acetic and Hydroxamic Acids as Novel Lipoxygenase Inhibitors
Medicinal Chemistry New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Agave (Agave spp.) and its Traditional Products as a Source of Bioactive Compounds
Current Bioactive Compounds Emerging Therapies in Chronic Myeloid Leukemia
Current Cancer Drug Targets Novel Options for the Pharmacological Treatment of Chronic Anal Fissure – Role of Botulin Toxin
Current Clinical Pharmacology Coronavirus Disease -2019 (COVID-19) in 2020: A Perspective Study of a Global Pandemic
Current Pharmaceutical Design Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Assessment of Cardiac Safety for PPARγ Agonists in Rodent Models of Heart Failure: A Translational Medicine Perspective
Current Molecular Pharmacology Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Serum Levels of IL-6, TNF-α and IL-10 as Early Predictors of Mortality in Trauma Hemorrhagic Shock Patients
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)